ENGLEWOOD, Colo., July 27, 2021 /PRNewswire/ -- Ampio
Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology-based therapies
for prevalent inflammatory conditions, today announced details on
the Company's poster presentation, "Inflammation and COVID Induced
ARDS: Inhaled Ampion™ as a Therapeutic Option," being given at the
63rd annual Thomas L. Petty Aspen Lung Conference, September 20 to 23, 2021, at the Gant Conference
Center in Aspen, Colorado.
Elevated levels of inflammatory cytokines indicative of an
uncontrolled immune response have been found in COVID-19 patients
with ARDS, and in vitro studies indicate Ampion
regulates cellular transcription to reduce inflammatory cytokines
(TNFα, IL-1β, IFNγ, IL-6, IL-12, IP-10).
Ampio's poster highlights the Company's recently completed
AP-014 Phase I clinical trial utilizing an inhaled form of Ampio's
drug, Ampion, for treatment of respiratory distress in patients as
a result of COVID-19. The study showed inhaled Ampion reduced
all-cause mortality in COVID-19 respiratory distress by 78% over
the Standard of Care (SOC) alone.
In addition, the poster further highlights that patients
who received inhaled Ampion had shorter hospital stays (8 days for
Ampion vs. 12 days for control) and shorter ICU stays (8 days for
Ampion vs. 11 days for control). Remdesivir was also used at a
lower rate (26% of patients) in the Ampion group vs. the control
group (52% of patients).
The poster is led by Michael
Roshon, M.D., Ph.D., of the Emergency Department, Penrose
Hospital (Colorado Springs, CO)
and Luciano Lemos-Filho, M.D., of
the National Jewish Division of Pulmonary Medicine at Swedish
Medical Center (Englewood,
CO).
The theme of this year's Aspen Lung Conference will be "ARDS in
the 21st Century: New Insights into Clinical and Mechanistic
Heterogeneity," providing an international forum bringing together
leading basic, translational, and clinical ARDS researchers while
welcoming trainees in pulmonology and critical care medicine. The
conference will be a hybrid event, mixing in-person and virtual
sessions, with all poster sessions being held virtually.
For more information on the poster presentation or the Aspen
Lung Conference, visit https://medschool.cuanschutz.edu/aspen.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2037 and will be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the biologics
price competition and innovation act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified using words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as well
as those associated with regulatory approvals and other FDA
decisions, the Biological License Application (BLA), the ability of
Ampio to enter into partnering arrangements, clinical
trials and decisions and changes in business conditions and similar
events, the ability to receive regulatory approval to conduct
clinical trials, that Ampion may be used to treat ARDS induced by
COVID-19, all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include those
detailed from time to time in Ampio's filings with the Securities
and Exchange Commission, including without limitation, under
Ampio's Annual Report on Form 10-K and other documents filed with
the Securities and Exchange Commission. Ampio undertakes no
obligation to revise or update these forward-looking statements,
whether because of new information, future events or otherwise.
Media Contact
Katie Kennedy
katiek@gregoryfca.com
610-731-1045
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-present-at-aspen-lung-conference-301341959.html
SOURCE Ampio Pharmaceuticals, Inc.